GCVI Summit 2018
Skip Content

4 March 2016

Syndax synchronises with public markets

The cancer treatment developer raised $52.8m, floating beneath its $14 to $16 range, as existing backer Fidelity invested $8m.

Author: Robert Lavine, News Editor

Syndax Pharmaceuticals, an oncology treatment developer that counts financial services group Fidelity Management and Research among its investors, raised $52.8m when it floated on Nasdaq yesterday.